Petros Pharma 8-K: Financial Obligation Trigger Event
Ticker: PTPI · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1815903
| Field | Detail |
|---|---|
| Company | Petros Pharmaceuticals, Inc. (PTPI) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $7,246,634.90, $237,300.35, $2,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-obligation, trigger-event, debt
TL;DR
Petros Pharma 8-K filed: Financial obligation trigger event. Watch for details.
AI Summary
On December 10, 2024, Petros Pharmaceuticals, Inc. filed an 8-K report to disclose a triggering event related to its financial obligations. The filing indicates a potential acceleration or increase in a direct financial obligation or an obligation under an off-balance sheet arrangement. Specific details regarding the nature of the obligation and the exact financial impact are not provided in this summary section of the filing.
Why It Matters
This filing signals a potential change in Petros Pharmaceuticals' financial commitments, which could impact its financial health and future operations.
Risk Assessment
Risk Level: medium — The filing indicates a triggering event for financial obligations, which could lead to increased debt or accelerated payments, posing a moderate risk.
Key Players & Entities
- Petros Pharmaceuticals, Inc. (company) — Registrant
- December 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 (address) — Principal executive offices
FAQ
What specific financial obligation is being triggered?
The filing does not specify the exact financial obligation, only that a triggering event has occurred that could accelerate or increase a direct financial obligation or an obligation under an off-balance sheet arrangement.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is December 10, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the SIC code for Petros Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Petros Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 759 words · 3 min read · ~3 pages · Grade level 14 · Accepted 2024-12-16 17:15:26
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PTPI The Nasdaq Stock Marke
- $7,246,634.90 — npaid amount of the Promissory Note was $7,246,634.90 in principal and $237,300.35 in interes
- $237,300.35 — Note was $7,246,634.90 in principal and $237,300.35 in interest. Interest continues to accr
- $2,000,000 — l would only constitute satisfaction of $2,000,000 worth of the Obligations and would not
Filing Documents
- tm2431088d1_8k.htm (8-K) — 26KB
- 0001104659-24-128984.txt ( ) — 197KB
- ptpi-20241210.xsd (EX-101.SCH) — 3KB
- ptpi-20241210_lab.xml (EX-101.LAB) — 33KB
- ptpi-20241210_pre.xml (EX-101.PRE) — 22KB
- tm2431088d1_8k_htm.xml (XML) — 4KB
04 Triggering Events That Accelerate or Increase a Direct
Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on January 21, 2022, Metuchen Pharmaceuticals LLC ("Metuchen"), a wholly owned subsidiary of Petros Pharmaceuticals, Inc. (the "Company"), entered into that certain (a) Settlement Agreement (the "Settlement Agreement") and Security Agreement (the "Security Agreement"), each dated January 18, 2022, with Vivus LLC (the "Secured Party") and (b) Promissory Note dated January 18, 2022, payable to the order of the Secured Party (the "Promissory Note"). As a result of an event of default under the Settlement Agreement and the Security Agreement existing and continuing by virtue of Metuchen's failure to pay the Installment (as defined in the Promissory Note) that was due October 1, 2024, all the obligations of Metuchen under the Settlement Agreement and the Security Agreement (the "Obligations") became immediately due and payable on the date of the Foreclosure Notice (as defined below). As of December 10, 2024, the unpaid amount of the Promissory Note was $7,246,634.90 in principal and $237,300.35 in interest. Interest continues to accrue on the foregoing amount at the default rate of 9% per annum. Pursuant to the Security Agreement, the Secured Party holds a security interest against the Collateral (as defined in the Foreclosure Notice). On December 10, 2024, pursuant to a Notice of Proposal to Accept Pledged Collateral in Partial Satisfaction of Indebtedness Pursuant to Uniform Commercial Code Section 9-620 (the "Foreclosure Notice"), the Secured Party proposed to accept all the Collateral (save and except the Specified License Agreement (as defined in the Security Agreement); collectively, the "Foreclosed Collateral") in partial satisfaction of the Obligations. The Secured Party further proposed in the Foreclosure Notice
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PETROS PHARMACEUTICALS, INC. Date: December 16, 2024 By: /s/ Fady Boctor Name: Fady Boctor Title: President and Chief Commercial Officer